Welcome to our media centre, here you will find a range of resources including our press releases, news updates and information related to the conferences and events we attend each year.
These press releases and news updates are intended for media and investors only.
UPCOMING CONGRESS
13-17 JULY 2025
IAS Conference on HIV Science (IAS)
IAS is one of the largest medical conferences in the HIV calendar. For physicians, researchers, and the wider HIV community, it's a chance to discover the latest advances in HIV treatment and care.
08 JULY 2025
ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025
27 MAY 2025
ViiV Healthcare Positive Perspectives 3 study finds widespread communication barriers: Half of people living with HIV feel unheard by healthcare providers despite high trust
12 MAR 2025
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
12 MAR 2025
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
11 MAR 2025
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
09 Mar 2025
ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025
31 Jan 2025
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
16 Dec 2024
ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe
Media contacts
Media contact details for our global headquarters and USA. For press contacts in our local operating companies please visit our country websites.
If you have a media query please contact us
Global Press Office
Rachel Jaikaran
Head of Global Communications ViiV Healthcare
Tel: +44 7823 523 755
US Press Office
Todd Siesky
VP, Head of US Communications & External Affairs
Tel: +1 984 390 0345
NP-GBL-HVX-COCO-220039 | July 2025
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
